Valuation: Cosmos Holdings Inc.

Market Cap 11.94M 10.35M 9.7M 8.84M 16.63M 1.14B 16.88M 114M 44.58M 570M 44.85M 43.87M 1.9B P/E 2026 *
22x
P/E 2027 * 3.14x
Enterprise Value 11.94M 10.35M 9.7M 8.84M 16.63M 1.14B 16.88M 114M 44.58M 570M 44.85M 43.87M 1.9B EV / Sales 2026 *
0.14x
EV / Sales 2027 * 0.11x
Free-Float
63.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 26/02/2016
Director of Finance/CFO 43 11/11/2020
Chief Operating Officer 56 01/02/2023
Director TitleAgeSince
Director/Board Member 58 13/01/2014
Chairman 60 26/02/2016
Director/Board Member 59 18/11/2016
Change 5-day change 1-year change 3-year change Capi.($)
-5.65%-2.45% - - 11.94M
-1.02%+1.54%+35.17%+103.37% 105B
-1.43%-1.12%+61.69%+154.38% 55.88B
-0.34%-0.34%+4.59%+270.00% 24.12B
-0.78%-0.42%-13.12%-14.11% 8.28B
-1.04%+3.55%-30.67%-25.18% 7.75B
-0.48%-3.46%-11.56%-22.27% 6.69B
+0.48%+0.43%+18.27%+17.54% 6.16B
-1.41%-4.96%-5.85%+18.48% 5.01B
-0.59%-0.40%-6.15%-4.99% 3.75B
Average -1.22%+1.78%+5.82%+55.25% 24.75B
Weighted average by Cap. -1.02%+4.94%+30.94%+115.49%

Financials

2026 *2027 *
Net sales 84.3M 73.04M 68.43M 62.42M 117M 8.04B 119M 805M 315M 4.03B 317M 310M 13.42B 111M 96M 89.94M 82.04M 154M 10.57B 157M 1.06B 414M 5.29B 416M 407M 17.64B
Net income - -
Net Debt - -
Logo Cosmos Holdings Inc.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Employees
-

Quarterly revenue - Rate of surprise